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INTRODUCTION
Although cyclosporin A (CsA) has been hailed as a major
advance in transplantation, increasing both graft and patient
survival, its use is sometimes limited by nephrotoxicity and
hyperkalemia which have been commonly observed in renal
transplant patients successfully treated with cyclosporine (1,
2). The pathogenesis of CsA-induced nephrotoxicity remains
unclear. Intrarenal vasoconstriction at the level of the afferent
glomerular arteriole is at the cornerstone of the pathogenesis
(3, 4), but its mechanism has not been fully elucidated.
Another common complication of CsA-treatment is hyper-
kalemia. Formerly, several reports have suggested that the
development of hyperkalemia is specifically associated with
the therapeutic administration of CsA, and it was believed
that the mechanism of hyperkalemia involved the reduction
of potassium secretion as a result of renal tubular damage and
hypoaldosteronism (2, 5). But recently, Suzuki et al. (6) reported
that prolonged use of CsA suppresses DNA and RNA syn-
thesis, as well as Na
+, K
+-ATPase activity in the renal cortex
and subsequently damages the tubular basement membrane
resulting in nephrotoxicity and hyperkalemia. This finding
has been confirmed by Ihara et al. (7), Tumlin et al. (8), and
Anderson et al. (9) in experiments with rodents. 
Thyroxine administration has shown protective effects in
several experimental models of acute renal failure induced
by various and numerous nephrotoxic agents. These effects
have been associated with a rise of Na
+, K
+-ATPase activity
in the basolateral membranes of renal tubules (10-14). 
We designed the present experiment to examine the protec-
tive effects of thyroxine on CsA nephrotoxicity and hyper-
kalemia by comparing the Na
+, K
+-ATPase activity in renal
tubular cells and the level of potassium.
MATERIALS AND METHODS
Drugs
CsA (Sandimmune, Sandoz Co, Swiss) and L-thyroxine
(Sigma Chemical, St. Louis, MO, U.S.A.) were used for the
study. The thyroxine was dissolved in 0.01 N NaOH to a
concentration of 100 g/mL and stored at 20℃before used. 
Experimental protocol
Twenty-six pathogen-free, male, Sprague-Dawley rats
weighing 200-230 g were assigned to one of the following
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Effects of Thyroxine on Hyperkalemia and Renal Cortical Na
+, K
+-
ATPase Activity Induced by Cyclosporin A
Cyclosporin A (CsA)-induced hyperkalemia is caused by alterations in trans-
epithelial K
+ secretion resulting from the inhibition of renal tubular Na
+, K
+-ATPase
activity. Thyroxine enhances renal cortical Na
+, K
+-ATPase activity. This study
investigated the effect of thyroxine on CsA-induced hyperkalemia. Sprague-Daw-
ley rats were treated with either CsA, thyroxine, CsA and thyroxine, or olive-oil
vehicle. CsA resulted in an increase in BUN and serum K
+, along with a decrease
in creatinine clearance, fractional excretion of potassium, and renal cortical Na
+,
K
+-ATPase activity, as compared with oil vehicle administration. Histochemical
study showed reduced Na
+, K
+-ATPase activity in the proximal tubular epithelial
cells of the CsA-treated compared with the oil-treated rats. Histologically, isomet-
ric intracytoplasmic vacuolation, disruption of the arrangement and swelling of
the mitochondria, and a large number of lysosomes in the tubular epithelium were
characteristic of the CsA-treated rats. Co-administration of thyroxine prevented
CsA-induced hyperkalemia and reduced creatinine clearance, Na
+, K
+-ATPase
activity, and severity of the histologic changes in the renal tubular cells when com-
pared with the CsA-treated rats. Thyroxine increased the fractional excretion of
potassium via the preservation of Na
+, K
+-ATPase activity in the renal tubular cells.
Thus, the beneficial effects of thyroxine may be suited to treatment modalities
for CsA-induced hyperkalemia.
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four groups of treatment: group 1 (N=5), olive-oil vehicle;
group 2 (N=7), thyroxine (25  g/kg) subcutaneously; group
3 (N=7), CsA (25 mg/kg) intraperitoneal injection; group 4
(N=7), thyroxine (25  g/kg) subcutaneous injection followed
by CsA (25 mg/kg) intraperitoneal injection one hour later.
All studies were carried out for 30 days and all rats were pair-
fed using tap water and standard rat chow to control effects
of cyclosporine-induced weight loss. The dose of thyroxine
(25  g/kg) used in this experiment was 20- to 320-fold lower
than those used in previous experiments to study hyperthy-
roidism in this species (15). 
Measurement of physiologic and blood chemistry data
The following measurements, including body weight, were
taken before initiation of therapy and immediately prior to
sacrifice after 30 days of drug administration. The systolic
blood pressures (SBP, means of three measurements) were
measured in unanesthetized rats by plethysmography with a
rat tail manometer-tachometer system (Natsume Seisakusho
Co. Ltd., Tokyo, Japan). The serum collected for BUN, cre-
atinine concentration, and creatinine clearance was analyzed
by a Hitachi 747 autoanalyzer (Hitachi Co. Japan). Creatinine
clearance was calculated by a standard formula. The serum
concentration of potassium and fractional excretion of potas-
sium (FEK) were analyzed by an Atra-8 autoanalyzer (Beck-
man Co. Palo Alto, CA, U.S.A.). In the rats receiving CsA,
the trough concentrations of the drug were measured on day
30 by fluorescence polarization immunoassay (TDX, Abbott
Lab., Abbott Park, IL, U.S.A.) using whole blood.
On day 30, the rats were anesthetized with an intraperi-
toneal injection of pentobarbital at a dose of 30-50 mg/kg,
and the kidney was exposed with a midline incision and
stripped of its capsule. After 3-5 mL of blood had been ob-
tained from the descending aorta, this vessel was ligated just
above the origin of the renal artery. The kidney was emptied
of blood by perfusion (250 mM sucrose, 10 mM HEPES
buffer, 0.5 mM EDTA) using a catheter, and the organs were
removed and sliced into 0.5- to 1-mm sections in dishes re-
sting on ice. The cortex was dissected out, placed on filter
paper, and weighed after removing water on the surface. Serum
was separated from the blood sample and stored at -20℃
until assayed. Renal function markers and electrolyte con-
centrations were measured within 5 days.
Separation of microsomal fraction in renal cortex tissue
The microsomal fraction was obtained using a modification
of the Jørgensen and Skou’s method (16). Perfusion solution
was added to the renal cortical tissue (20 mL/g), and the tis-
sue was homogenized by 10 strokes in a glass homogenizer
with a Teflon pestle at 1,500 rpm. The homogenate was cen-
trifuged at 1,300 g for 10 min at 4℃ in a Beckman J2-MC
refrigerated centrifuge. The supernatant fluid was saved, and
the pellet was resuspended in half the original volume of
sucrose buffer and centrifuged as above for 10 min at 1,300
g. The supernatant fluid was decanted and combined with
the previous supernatant material (Fraction 1). Fraction 1 was
centrifuged at 9,500 g for 15 min, and the resulting super-
natant fluid and the fluffy layer of the pellet were removed
by a Pasteur pipette and pooled as Fraction 2. Fraction 2 was
centrifuged at 25,000 g for 30 min. The supernatant fluid
and the dark lower pellet were discarded, and the upper fluffy
pellet was resuspended in sucrose buffer. This fraction (Frac-
tion 3) contained the microsomes and was stored at -70℃,
either for later measurement of enzyme activity or for imme-
diate use. The protein concentration was measured by the
method of Lowry et al. (17) using bovine serum albumin as
a standard after the tissue preparations had been adjusted to
a protein concentration of 1 m/L. 
Measurement of Na+, K+-ATPase in kidney tissues
The Na
+, K
+-ATPase activity was measured by the Jørgensen
and Skou’s method (16). Microsomal-fraction protein (150  g
in 600  L of a solution consisting of 12.5 mM imidazole and
1 mM EDTA) was incubated at 25℃ for 30 min, and the
enzyme activity was measured by determining the amount of
inorganic phosphate liberated from ATP in 1 mL of a solu-
tion containing 130 mM NaCl, 20 mM ATP, 3 mM MgCl2,
30 mM L-histidine, 10 mM HEPES buffer (pH 7.5), and
25  L of microsomal-fraction protein. The solution (100  L)
was mixed with 0.8 mL of buffer solution for measurement
of total ATPase and Mg2+-ATPase. The ATPase reaction was
initiated by the addition of 100  L of 3 mM ATP after a 10-
min equilibration in a 37℃ waterbath. The reaction was
carried out in the presence or absence of 1 mM ouabain and
terminated with 0.3 mL of 6% perchloric acid. The solution
was centrifuged at 2,000 gfor 15 min at 4℃, and the amount
of Pi was measured at 660 nm in a spectrophotometer using
the Fiske and Subbarow method (18). The enzyme activity
suppressed by the addition of ouabain was considered equiv-
alent to the activity of Na
+, K
+-ATPase and was expressed
as mole Pi/mg of protein per hour. 
Detection of the distribution of Na+, K+-ATPase in kidney
tissues by histochemistry
The distribution of Na
+, K
+-ATPase in kidney tissues was
determined using a modification of the method of Mayahara
et al. (19). The renal cortical tissue was perfused with solu-
tion containing 2% polyvinyl pyrrolidone, 0.8 mM CaCl2,
and 100 mM histidine (pH 7.25) with 0.1 M KOH for 15
to 20 min and then refrigerated at -60℃ with dry ice-ace-
tone. After placement in N-methylbutane for 2 to 5 min, the
tissue was frozen at -20℃. Frozen sections in 5 to 24  m
thickness were cut and then dried at room temperature for
15 to 20 min. The dried tissue was incubated in a 20 mLsolution consisting of 30 mM KCl, 5 mM MgCl2, 5 mM  -
nitrophenylphosphate, and 70 mM 2-amino-2-methyl-1-
propanol buffer (pH 9.0) with the addition of 1 mM ouabain
at 37℃for 1 to 3 hr and then placed in 2% CoCl2 for 5 min.
The tissue was then rinsed with distilled water, washed with
2-amino-2-methyl-1-propanol buffer (79 mM; pH 9.0) three
times for 30 sec each, placed in light ammonium sulfide
(diluted 1:50 v/v) for 3 min, and rinsed again in distilled
water. The specimens were then dried with alcohol and xylene
and fixed for light microscopic examination.
Histopathology of kidney tissues
Light microscopic analysis was made on periodic acid-Schiff
(PAS) stained thin kidney sections. For electron microscopy,
tissues were prefixed in 0.5% glutaraldehyde, postfixed in
1% osmium tetroxide, dehydrated in a graded alcohol series
and propylene oxide, and embedded in a Epon mixture solu-
tion. Thin sections were cut with a diamond knife, stained
with uranyl acetate on a 100-mesh grid, and examined with
a Hitachi HS-9 electron microscope at 75 kV.
Statistical analysis
The results were expressed as mean±SE. Statistical signif-
icance was determined by the Wilcoxon rank sum test, with
a pvalue of less than 0.05 being considered significant. 
RESULTS 
Body weight and blood pressure data
The experimental technique of pair feeding controlled to
a relatively effective degree for cyclosporine-induced reduc-
tion of dietary intake. There were no significant differences
in the final body weights at sacrifice among the experimental
rats over the 30 days of our study, except the CsA-treated rats
which gained 8 g, and the oil-treated rats which gained 33
g. CsA treatment alone resulted in a slight but not signifi-
cant elevation in SBP, as compared with the oil-treated rats.
There was no significant difference in body weight among
any of the four groups (Table 1).
Blood chemistry data
Intergroup comparison on day 30 showed a two-fold in-
crease of the BUN concentration in the CsA-treated rats, com-
pared with the oil-treated rats (46.4±5.3 vs 20.5±4.2 mg/L,
p<0.05). Serum creatinine concentrations in the CsA-treated
rats also rose significantly compared with both the oil-treat-
ed rats and thyroxine-treated rats (1.0±0.3 vs. 0.7±0.2 and
vs. 0.5±0.2 mg/dL, respectively, p<0.05). Creatinine clear-
ance was significantly lower in the CsA-treated rats (3.8±
1.1 L/mg day p<0.05) and lower, although not significantly,
in the CsA+thyroxine-treated rats (5.4±1.6 L/mg day, p<NS)
than in the oil-treated rats (6.2±2.4 L/mg day) (Table 2).
Administration of thyroxine alone had no effect on BUN,
serum creatinine, or creatinine clearance. No significant dif-
ference in the serum CsA level was observed in the CsA-treat-
ed and CsA+thyroxine-treated rats (2.954±1.003 vs 3.126
±1.362 ng/mL). 
Serum potassium and fractional excretion of potassium
(FEK)
The serum potassium concentration was higher in the CsA-
treated rats than in oil-treated rats (5.2 vs 4.5 mEq/L, p<0.05),
but showed no significant difference among the oil-treated,
thyroxine-treated, and CsA+thyroxine-treated rats (Fig. 1).
The FEK value was significantly lower in the CsA-treated
rats than in the oil-treated rats (40±15.1 vs 61.2±2.4%,
p<0.05). No significant difference in the FEK value was ob-
served between the thyroxine-treated and oil-treated rats
(Fig. 2). Hyperkalemia was found to correlate with the FEK
value in the CsA-treated rats.
Na+, K+-ATPase activity in the renal cortical microsomal
fraction
Na
+, K
+-ATPase activity was significantly lower in the CsA-
treated rats than in the oil-treated rats (37.5±6.5 vs 17.5
±7.7 mole pi/mg protein/hr, p<0.05) (Fig. 3), whereas no
significant difference was observed between the oil-treated
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Oil (N=5) 215.4±7.3 248.3±9.4 92.7±17.4 95.0±5.0 
Thyroxine (N=7) 207.7±9.2 228.5±6.6 89.4±9.4 90.4±7.3
CsA (N=7) 224.6±6.2 232.3±5.5 90.5±10.5 95.0±16.4
CsA+Thyroxine 
(N=7) 213.3±5.7 236.4±4.7 94.6±12.3 96.6±9.5
Table 1. Changes in body weight and systolic blood pressure
from initial to final measurement in study groups
Initial
Body weight (g) Systolic blood 
pressure (mmHg) Groups 
Final  Initial Final 
Values are expressed as mean±SE. CsA: cyclosporin A.
Oil (N=5) 20.5±4.2 0.7±0.2 6.2±2.4 -
Thyroxine (N=7) 22.4±5.2 0.5±0.2 5.8±1.9 -
CsA (N=7) 46.4±5.3* 1.0±0.3 3.8±1.1* 2,954±1,003
CsA+Thyroxine
(N=7) 24.9±2.7 0.6±0.3 5.4±1.6 3,126±1,362
Table 2. Effect of thyroxine on glomerular function and cyclo-
sporine blood level
Creatinine
(mg/dL)
Ccr   
(L/mg day) 
CsA blood
level (ng/mL)  Groups BUN  (mg/L)
Values are expressed as mean±SE. BUN, blood urea nitrogen; Ccr,
creatinine clearance; CsA, cyclosporin A. *p<0.05  compared with oil.and CsA+thyroxine-treated rats.
Histochemical staining of Na+, K+-ATPase in the kidney
The staining extent was determined by the relative abun-
dance of different nephron segments in each zone including
outer medulla, cortex, and inner medullary papilla. The great-
est degree of staining was detected in the thick ascending
loop of Henle in the outer medulla and distal convoluted
tubule in both oil and thyroxine-treated rats. The enzymatic
reaction was markedly reduced in the proximal tubules of
CsA-treated rats compared with the oil-treated rats, but there
was no significant difference between the oil-treated rats and
CsA+thyroxine-treated (Fig. 4).
Histopathologic effect of thyroxine in CsA-treated rat
kidney
Light microscopically, no morphological changes were not-
ed either in the kidneys treated with oil or those with thy-
roxine alone. In the CsA-treated rat kidneys, morphological
changes were noted along the entire length of the proximal
tubules. The light microscopic alterations were confined to
the thick ascending loop of Henle at the cortico-medullary
junction, and consisted of cytoplasmic swelling, cytoplasmic
vacuolation of varying degrees, and small PAS-positive gran-
ules. Frank cell necrosis was not present. In some areas, all
the cells lining a tubule were affected, while in others only
alternate or fewer cells were involved. The vacuolation varied
from fine sub-nuclear cytoplasmic stippling to large vacuoles
measuring up to 5  m in diameter. Although these findings
were also noted in the CsA+thyroxine-treated rat kidneys,
the tubular epithelial cytoplasmic swelling was milder with
fewer cytoplasmic granules in this group than in the CsA-
treated ones (Fig. 5). Electron microscopically, no morpho-
logical changes were noted in cells of the renal corpuscle from
the oil and thyroxine-treated rats. The localized proximal
tubular cytoplasmic vacuolation visible on light microscopy
was due to dilatation of the endoplasmic reticulum. Both
smooth and rough endoplasmic reticulum were affected. The
small PAS-positive granules found in the CsA-treated and
CsA+thyroxine-treated rat kidneys were primary and sec-
ondary lysosomes in the proximal tubular epithelial cells.
Furthermore, disruption of arrangement including variation
of the size and shortening of the cristae, along with swelling
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Fig. 1. Serum potassium levels in study groups after 30 days of
thyroxine, cyclosporin A, and cyclosporin A+thyroxine adminis-
tration. *p<0.05: compared with control.
*
F
E
K
,
 
%
80
70
60
50
40
30
20
10
0
Control Thyroxine Cyclosporin A Cyclosporin A
+Thyroxine
Fig. 2. Fractional excretion of potassium (FEK) in study groups
after 30 days of thyroxine, cyclosporin A, and cyclosporin A+
thyroxine administration. *p<0.05: compared with control.
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Fig. 3. Renal cortical Na+, K+-ATPase activities in study groups
after 30 days of thyroxine, cyclosporin A, and cyclosporin A+
thyroxine administration. *p<0.05: compared with control.
*of the mitochondria, was also found. Light microscopic find-
ings of the CsA+thyroxine-treated rats indicated a marked
reduction in the number of lysosomes and disruption of the
mitochondria (Fig. 6).
DISCUSSION
Anderson et al. (9) reported that an increase in lysophos-
phatidyl choline, generated by inhibition of Na
+, K
+-ATPase
activity during CsA treatment of mitogen- or antigen-acti-
vated lymphocytes, represented a possible mechanism for the
immunosuppressive activity of CsA. Moreover, the decrease
in Na
+, K
+-ATPase is secondary to a change in the arachidon-
ic acid metabolism or in the binding of CsA and the alpha
subunit of the enzyme. These findings suggest that the im-
munosuppressive effect of CsA may result from its suppres-
sion of Na
+, K
+-ATPase activity in lymphocytes.
Also, Ihara et al. (7) found that potassium release from hu-
man erythrocytes after CsA treatment is attributable mainly
to the activation of the K
+channel and partial inhibition of
Na
+, K
+-ATPase by CsA, suggesting that the K
+ efflux might
be one of the underlying mechanisms of hyperkalemia. Adu
et al. (5) reported that the etiologic factors of hyperkalemia
and hyperchloremic acidosis could be caused by hypoaldos-
teronism or renal tubular resistance to the action of aldos-
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Fig. 4. Na
+, K
+-ATPase reaction of the proximal tubular epithelial cells by using frozen tissue section is remarkably reduced in cyclosporin
A administered group (A) compared to normal control (B). Reduction of Na
+, K
+-ATPase reaction is partly protected when cyclosporin
A was administered with thyroxine (C).
A B C
Fig. 5. Presence of small cytoplasmic hyaline globules in proximal tubular cells in addition to cytoplasmic edema is a characteristic find-
ing of cyclosporin A administered group (A). These findings are attenuated in number when thyroxine is added although cytoplasmic
edema is still noted.
A Bterone or renal tubular damage leading to a tubular defect of
potassium and hydrogen secretion. Tumlin and Sands (8)
reported that the cause of CsA-induced hyperkalemia is not
hypoaldosteronism but rather a direct result of the inhibi-
tion of Na
+, K
+-ATPase in the renal tubule.
Na
+, K
+-ATPase is an integral membrane protein present
in all mammalian cells. By actively pumping sodium ions
out of cells and potassium ions into cells, the enzyme gener-
ates a sodium ion gradient that is used by the cell to run a
variety of secondary Na
+-dependent transport reactions.
Glucose, amino acids, and essential ions such as hydrogen
and phosphates are moved across the cell membrane by these
carriers. Thus, Na
+, K
+-ATPase is a key enzyme for cellular
homeostasis. When its function is reduced or lost, cellular
swelling and death occur (20). Potential factors involved in
the regulation of Na
+, K
+-ATPase are the supply of sodium,
potassium, phosphate ions, and a number of hormones
including chiefly adrenal corticosteroids, thyroid hormones,
and perhaps insulin. 
We investigated in this study whether exogenous thyrox-
ine decreased nephrotoxicity and hyperkalemia in CsA-treated
rats by physiologic and histologic investigation, biochemical
measurements and determination of Na
+, K
+-ATPase activity
in thin kidney sections. The data from this study demonstrate
the prevention/reduction of CsA-induced nephrotoxicity and
hyperkalemia by exogenous thyroxine in vivo, as evidenced
by histopathologic changes and Na
+, K
+-ATPase activity in
renal tissues. Our findings suggest that a potential mecha-
nism for CsA-induced hyperkalemia and nephrotoxicity may
be related to the tubular structural damage which results
from the inhibition of tubular Na
+, K
+-ATPase activity, and
that this damage is attenuated by exogenous thyroxine.
Thyroxine has been shown to play a afforded protective role
and stimulate Na
+, K
+-ATPase activity in experimental models
of acute renal failure, but the dose and time of administration
differed among the models. The influence of thyroxine on
normal renal function is well documented; as depressing the
glomerular filtration rate below normal in hypothyroidism,
whereas increasing it above normal in hyperthyroidism. How-
ever, it is unlikely that the protection provided by thyroxine
in the present study was due to the induction of a hyperthy-
roid state. The dose used in this study of 25  g/kg body
weight is 20- to 320-fold lower than those used in previous
studies on hyperthyroidism in rats. Furthermore, thyroxine
alone had no effect on renal hemodynamics, as demonstrat-
ed by the stable physiologic and blood chemistry data (11). 
CsA nephrotoxicity is manifested histologically as tubular
damage (6, 21, 22). The demonstration by Suzuki et al. (6)
of the relief of histologic damage and hyperkalemia by glu-
cocorticoid treatment suggests that the mechanism involves
stimulation of renal tubular Na
+, K
+-ATPase and gives sup-
port to the hypothesis that the adverse effects of CsA are in-
deed the result of a decrease in the activity of this enzyme. In
our study of CsA-induced nephrotoxicity and its prevention,
we used thyroxine, which is more effective than glucocor-
ticoids in preventing many kinds of renal toxicity (10-14).
Accurate measurement of Na
+, K
+-ATPase activity in the
mi-crosomal fraction is time-consuming and demanding, so
we also used a histochemical approach for the measurement
of the enzyme activity. The usefulness of the latter method
was confirmed by its indication of markedly reduced Na
+,
K
+-ATPase activity in the CsA-treated rats.
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Fig. 6. Ultrastructurally, cytoplasmic hyaline globules in light microscopy are proved as primary (arrows) and secondary (arrow heads)
lysosome (cyclosporine group: A). These are decreased in number in the thyroxine+cyclosporin A administered group.
A BOur finding of a lesser degree of histologic damage in the
rats receiving thyroxine suggests that the renal damage caus-
ed by CsA is the result of inhibition of Na
+, K
+-ATPase. Ac-
cording to Tumlin and Sands (8), the reduction of Na
+, K
+-
ATPase activity is detectable within 30 min after CsA admi-
nistration, even before the histologic change becomes appar-
ent. Thus, the inhibitory effect appears to be a direct action,
as opposed to a secondary effect. As a result of the inhibition,
an abnormal Na
+-gradient across the cell membrane arises,
leading to a disturbance of cellular homeostasis, and finally,
to histologically visible renal damage. Hyperkalemia also
results from the inhibition of this enzyme, although the exact
mechanism is not known.
These biochemical changes are accompanied by structural
damage, affecting the straight segment of the renal proxi-
mal tubule. The presence of increased numbers of lysosomes
throughout the proximal convoluted tubule indicates sub-
lethal cellular damage and is reflected in the increased level
of serum creatinine and decreased creatinine clearance. This
structural damage observed in the thick descending limb of
the loop of Henle is consistent with such an impairment of
sodium reabsorption from the tubule.
Cronin et al. (13) showed that both the number and size of
lysosomes were decreased when thyroxine was used to prevent
gentamicin nephrotoxicity. They suggested that the mecha-
nism of thyroxine’s protective effect involved the reduction
of drug uptake by pinocytosis and was related to increased
Na
+, K
+-ATPase activity. In our study on long-term CsA
(25 mg/kg for 30 days) administration, the kidney demon-
strated cytoplasmic vacuolation in proximal tubular epithe-
lial cells and deposition of lysosomes which were confirmed
by light and electron microscopy, although our experimen-
tal rats did not receive the large CsA doses (50 or 100 mg/
kg for 21 days) employed by Whiting et al. (21), nor a salt-
restricted diet. This change was attenuated by exogenous
thyroxine, which averted the reduction of Na
+, K
+-ATPase
activity. Also, the number of lysosomes was increased by
CsA administration and decreased by thyroxine co-adminis-
tration. It is probable that the decreased Na
+, K
+-ATPase
activity and increased number of lysosomes are related
events, however, because the amount of CsA in the lyso-
somes was not measured, it is not clear whether thyroxine’s
protective effect resulted from the reduction of the amount
of nephrotoxic material influx into the renal tubular cells or
from the increased Na
+, K
+-ATPase activity. To date, hyper-
kalemia has easily been managed by cation exchange resins
and CsA may be used in other medical conditions than organ
transplantation. So we recommend that the serum concen-
tration of potassium be carefully monitored when CsA is
administered to patients with conditions associated with
impaired potassium metabolism or to those receiving other
drugs that influence the disposition of potassium (3).
In conclusion, our study demonstrates that CsA-induced
hyperkalemia is associated with decreased Na
+, K
+-ATPase
activity and increased lysosomal levels, and that thyroxine
treatment attenuates this reduction of Na
+, K
+-ATPase activi-
ty. The administration of thyroxine may be useful in control-
ling CsA-mediated hyperkalemia. Further studies measuring
the amount of CsA in the lysosomes are necessary to elucidate
the thyroxine protection mechanism.
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